Skip to main content
. 2021 Sep 1;125(10):1377–1387. doi: 10.1038/s41416-021-01528-1

Fig. 1. Apalutamide radio-sensitises PCa cells in vitro.

Fig. 1

Viability radiation dose–response curves of the 22Rv1, PC3, and DU145 prostate cancer cell lines, exposed to bicalutamide, apalutamide, or no drug (control), in standard medium (a, c, e) and testosterone-enriched medium (b, d, f). Clonogenic radiation dose–response curves of 22Rv1, PC3, and DU145 prostate cancer cell lines exposed to apalutamide (g, h, i). Viability radiation dose–response curves of 22Rv1, PC3, and DU145 prostate cancer cell lines exposed to escalated doses of apalutamide in testosterone-enriched medium (j, k, l).